Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study

Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study

Abstract Background While disease progression can be readily monitored in early stage relapsing multiple sclerosis (MS), it is more challenging for secondary progressive multiple sclerosis (SPMS). This advanced stage of disease has distinct pathophysiology due to compartmentalization of neuroinflamm...

Full description

Bibliographic Details
Main Authors: Gill A. Webster, Dalice A. Sim, Anne C. La Flamme, Nancy E. Mayo
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Pilot and Feasibility Studies
Subjects:
Secondary progressive multiple sclerosis
MIS416
Immune modulator
Myeloid cells
Neurological improvement
Performance related outcome
Online Access:http://link.springer.com/article/10.1186/s40814-017-0201-4

Internet

http://link.springer.com/article/10.1186/s40814-017-0201-4

Similar Items